La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Jafron BiomedicalLtd Crescita futura

Future criteri di controllo 6/6

Jafron BiomedicalLtd prevede che gli utili e i ricavi cresceranno rispettivamente di 26.9% e 25.6% all'anno. Si prevede che l'EPS crescerà di 26.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 26.1% in 3 anni.

Informazioni chiave

26.9%

Tasso di crescita degli utili

26.5%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	22.6%
Tasso di crescita dei ricavi	24.5%
Rendimento futuro del capitale proprio	26.4%
Copertura analitica	Low
Ultimo aggiornamento	14 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

May 28

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

May 24

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

May 08

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

May 02

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Apr 13

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Mar 22

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Mar 04

Previsioni di crescita degli utili e dei ricavi

SZSE:300529 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	4,498	1,391	N/A	1,360	4
12/31/2025	3,651	1,054	N/A	1,044	4
12/31/2024	2,889	819	N/A	699	4
6/30/2024	2,406	711	926	1,229	N/A
3/31/2024	2,094	525	877	1,185	N/A
12/31/2023	1,922	436	669	917	N/A
9/30/2023	1,952	440	790	949	N/A
6/30/2023	1,949	419	609	872	N/A
3/31/2023	2,367	751	630	995	N/A
1/1/2023	2,491	890	408	884	N/A
9/30/2022	2,919	1,207	589	1,108	N/A
6/30/2022	3,041	1,325	670	1,206	N/A
3/31/2022	2,794	1,249	634	1,143	N/A
1/1/2022	2,675	1,197	712	1,249	N/A
9/30/2021	2,417	1,111	550	1,129	N/A
6/30/2021	2,269	1,055	575	1,110	N/A
3/31/2021	2,151	974	554	1,043	N/A
12/31/2020	1,951	875	600	957	N/A
9/30/2020	1,776	780	441	696	N/A
6/30/2020	1,643	706	431	669	N/A
3/31/2020	1,516	626	421	640	N/A
12/31/2019	1,432	571	363	583	N/A
9/30/2019	1,290	514	319	541	N/A
6/30/2019	1,219	498	236	465	N/A
3/31/2019	1,105	442	215	423	N/A
12/31/2018	1,017	402	211	384	N/A
9/30/2018	925	387	127	321	N/A
6/30/2018	846	345	161	317	N/A
3/31/2018	777	315	N/A	308	N/A
12/31/2017	718	284	N/A	304	N/A
9/30/2017	662	266	N/A	293	N/A
6/30/2017	612	251	N/A	283	N/A
3/31/2017	566	215	N/A	205	N/A
12/31/2016	544	202	N/A	179	N/A
9/30/2016	537	204	N/A	182	N/A
6/30/2016	547	209	N/A	192	N/A
3/31/2016	532	210	N/A	195	N/A
12/31/2015	509	200	N/A	205	N/A
12/31/2014	371	160	N/A	137	N/A
12/31/2013	304	127	N/A	133	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 300529 ( 26.9% all'anno) è superiore al tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 300529 ( 26.9% all'anno) cresceranno più rapidamente del mercato CN ( 21.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 300529 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 300529 ( 25.6% all'anno) crescerà più rapidamente del mercato CN ( 13.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 300529 ( 25.6% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 300529 sarà elevato tra 3 anni ( 26.1 %)

Jafron BiomedicalLtd Crescita futura

Future criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates fall by 13%

Price target decreased to CN¥56.67

Price target decreased to CN¥73.99

Price target raised to CN¥95.66

Price target raised to CN¥52.96

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.10 in 2Q 2023)

Jafron Biomedical Co.,Ltd. to Report First Half, 2024 Results on Aug 08, 2024

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

Dividend reduced to CN¥0.40

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

Now 20% overvalued after recent price rise

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.25 in 1Q 2023)

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Jafron Biomedical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 15%

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2022)

Consensus revenue estimates fall by 13%

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.51 in 2Q 2022)

Jafron Biomedical Co.,Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Jafron Biomedical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 31 May 2023

High number of new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in 2Q 2021)

Jafron Biomedical Co.,Ltd. Implements Final Cash Dividend (A Shares) for 2021, Payable on 10 June 2022

Jafron Biomedical Co.,Ltd. Approves Profit Distribution

Price target decreased to CN¥56.67

High number of new and inexperienced directors

Jafron Biomedical Co.,Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to CN¥73.99

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.23 in 3Q 2020)

Jafron Biomedical Co.,Ltd. (SZSE:300529) commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on September 14, 2021.

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.32 in 2Q 2020)

Investor sentiment deteriorated over the past week

Jafron Biomedical Co.,Ltd. Announces 2020 Final Profit Distribution, Payable on 12 May 2021

Full year 2020 earnings released: EPS CN¥1.10 (vs CN¥0.73 in FY 2019)

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: CN¥84.63

New 90-day low: CN¥64.16

Market pulls back on stock over the past week

Price target raised to CN¥95.66

New 90-day high: CN¥78.75

Price target raised to CN¥52.96

Third quarter earnings released

Jafron Biomedical Co.,Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day low: CN¥64.37

New 90-day high - CN¥77.44

Earnings released

Jafron Biomedical Co.,Ltd. to Report First Half, 2020 Results on Aug 26, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita